By contrast, Hyrina et al. [38] reported that miR-24 and miR-223 levels were significantly increased in patients who obtained an SVR with IFN-based antiviral treatment (Peg-IFN-α and RBV ± boceprevir (BOC) or telaprevir (TPV)), strongly suggesting the opposite effect of the pro-inflammatory IFN cytokine, possibly in combination with various factors, such as the genetic background and the different severity stages of liver disease. This evidence concerns the gene IFNA1 and liver disorder.